Cullinan Therapeutics Inc (NASDAQ: CGEM) on Friday, soared 3.92% from the previous trading day, before settling in for the closing price of $18.86. Within the past 52 weeks, CGEM’s price has moved between $7.64 and $30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. The company achieved an average annual earnings per share of 12.53%. With a float of $38.57 million, this company’s outstanding shares have now reached $42.90 million.
In an organization with 85 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cullinan Therapeutics Inc is 33.47%, while institutional ownership is 77.55%. The most recent insider transaction that took place on Jul 05 ’24, was worth 130,640. In this transaction Chief Scientific Officer of this company sold 8,000 shares at a rate of $16.33, taking the stock ownership to the 123,942 shares. Before that another transaction happened on May 06 ’24, when Company’s Chief Scientific Officer sold 58,000 for $28.07, making the entire transaction worth $1,628,159. This insider now owns 129,582 shares in total.
Cullinan Therapeutics Inc (CGEM) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.91 earnings per share (EPS) for the period topping the consensus outlook (set at -0.92) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.53% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Cullinan Therapeutics Inc (CGEM) is currently performing well based on its current performance indicators. A quick ratio of 28.87 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.26 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.47 million. That was inferior than the volume of 0.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.17%. Additionally, its Average True Range was 1.05.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 29.36%, which indicates a significant decrease from 95.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.49% in the past 14 days, which was lower than the 81.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.71, while its 200-day Moving Average is $16.74. However, in the short run, Cullinan Therapeutics Inc’s stock first resistance to watch stands at $19.96. Second resistance stands at $20.31. The third major resistance level sits at $20.94. If the price goes on to break the first support level at $18.98, it is likely to go to the next support level at $18.35. The third support level lies at $18.00 if the price breaches the second support level.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
Market capitalization of the company is 1.14 billion based on 57,634K outstanding shares. Right now, sales total 0 K and income totals -153,160 K. The company made 0 K in profit during its latest quarter, and -42,030 K in sales during its previous quarter.
